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ABSTRACT 
Objective: DC-SIGN participates in the initial stages of sexually transmitted HIV-1 
infection by recognizing highly mannosylated structures presented in multiple copies 
on HIV-1 gp120 and promoting virus dissemination. Inhibition of HIV interaction with 
DC-SIGN thus represents a potential therapeutic approach for viral entry inhibition at 
the mucosal level.  
Design: Herein we evaluate the efficacy in inhibiting HIV-1 infection and the potential 
toxicity of a multimeric glycomimetic DC-SIGN ligand (Dendron 12).  
Methods: The ability of Dendron 12 to block HIV-1 infection was assessed in cellular 
and human cervical explant models. Selectivity of Dendron 12 towards DC-SIGN and 
Langerin was evaluated by Surface Plasmon Resonance studies. β chemokines 
production following stimulation with Dendron 12 was also analyzed. Toxicity of the 
compound was evaluated in cellular and tissue models. 
Results: Dendron 12 averted HIV-1 trans infection of CD4+ T lymphocytes in 
presence of elevated viral loads and prevented HIV-1 infection of human cervical 
tissues, under conditions mimicking compromised epithelial integrity, by multiple 
clades of R5 and X4 tropic viruses. Treatment with Dendron 12 did not interfere with 
the activity of Langerin and also significantly elicited the production of the β 
chemokines MIP-1α, MIP-1β and RANTES. 
Conclusion: Dendron 12, thus, inhibits HIV-1 infection by competition with binding of 
HIV to DC-SIGN and stimulation of β chemokines production. Dendron 12 represents 
a promising lead compound for the development of anti-HIV topical microbicides. 
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Introduction 
HIV remains one of the leading causes of mortality and morbidity [1]. As the vast 
majority of HIV-1 infections occurs via sexual transmission through mucosal 
surfaces, the development of vaginal and rectal topical microbicides represents a 
promising approach to prevent sexually transmitted HIV-1 infection. 
DC-SIGN (dendritic cell-specific ICAM-3 grabbing non-integrin) is involved in the 
initial step of HIV-1 sexually transmitted infection and it may be considered a 
promising therapeutic target [2,3].  
Myeloid immature DCs located in mucosal tissue of vagina, cervix and rectum 
express DC-SIGN and are among the first cells to encounter sexually transmitted HIV 
[4-6]. Upon HIV-1 binding to DC-SIGN, the virus escapes (at least partially) 
degradation into lysosomes. Rather, it is internalised into endosomes and 
multivescicolar bodies, where it is protected from degradation and retained in a high 
infective state [7-9]. DCs transmit the virus in trans to adjacent CD4+ T lymphocytes 
in genital mucosae or, after migration to lymphoid tissue, to CD4+ T lymphocytes 
resident in lymphoid tissue, promoting HIV-1 dissemination [10-11]. DC-SIGN, 
facilitating HIV-1 interaction with CD4 and co-receptors, also enhances DCs infection 
in cis, that results in long term transmission of HIV [12,13].  
In addition, binding of HIV-1 to DC-SIGN activates signaling pathways that modulate 
Toll Like Receptors (TRLs) signaling, inducing immunosuppressive responses and 
triggering HIV replication and transmission [14-17].   
DC-SIGN specifically recognizes the high mannose glycan (Man9), presented in 
multiple copies on HIV-1 gp120 [8-18]. Fragments of Man9 terminated by a di- or a tri-
mannoside bind to DC-SIGN almost as efficiently as the entire Man9 [19]. Chemically 
synthesised analogues of (Man)9 terminal di- and tri-saccharides, are more resistant 
to hydrolysis by glycosydases than the corresponding natural oligosaccharides and 
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interact efficiently with DC-SIGN [20]. These analogues can be linked to tetravalent 
(dendrons) scaffolds to obtain compounds endowed with stronger binding affinities to 
DC-SIGN [21, 22]. Such compounds can compete with binding of HIV gp120 to DC-
SIGN and are suitable for the development of new anti-HIV microbicides. 
We recently demonstrated that a tetravalent dendron containing four copies of a 
linear pseudo-mannotrioside (Dendron 12) was able to inhibit HIV-1 trans infection of 
CD4+ T lymphocytes [23]. 
Experimental models based on infection with HIV of explants taken from human 
uterine cervix, albeit with some limitations, allow a better approximation of the 
conditions in vivo compared to cellular models [24-27]. Thus, in this study a cervical 
explant model was exploited to assess the efficacy in inhibiting HIV-1 infection and 
the toxicity of Dendron 12, with the purpose of evaluating if the compound is a 
suitable candidate for the development as topical microbicide. 
 
Material and Methods  
Cell culture 
 B-THP1 and B-THP1/DC-SIGN cells (contributed by Drs Li Wu and Vinet 
N.KevalRamani) were cultured as described [23].    
 
Virus 
The following HIV-1 strains were used: BaL (contributed by Drs. S. Gartner, M. 
Popovic and R. Gallo, DU174 (Source: Dr L Morris), the R5 and X4 tropic primary 
isolates 8g and DPMVF (provided by Prof. Stefano Aquaro).  
 
Inhibition of HIV infection in trans 
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Human CD4+ T lymphocytes  were purified from peripheral blood of volunteer healthy 
donors following written consent, and activated as described [23]. Dendron 12, 
synthesized as described [23], were diluted to desired concentration into culture 
medium (RPMI 160 with 20% FBS, Penicillin and Streptomycin (PS) and L-Glutamine 
(LG), (all from Euroclone, Siziano, Italy). B-THP1/DC-SIGN or B-THP1 cells (106 
cells/ml) were pre-incubated with Dendron 12 (250 µM), or culture medium alone for 
30’ prior to exposure to BaL (virus titer ranging from 5 TCID50 to 80 TCID50), in the 
continued presence of the inhibitor 3 h at 37 °C. After extensive washing, B-
THP1/DC-SIGN cells were co-cultured with activated human CD4+ T cells as 
previously described [23].  
 
Human cervical explants infection 
Cervical tissue was obtained, following written informed consent, from 
premenopausal women, HIV, HBV and HCV seronegative and without current genital 
infection, undergoing therapeutic hysterectomy at Unit of Obstetrics and 
Gynaecology of Sacco Hospital (Milan, Italy). The study was approved by the local 
ethic committee and conducted in compliance with international guidelines and local 
laws. Endocervical 3 mm x 3 mm explants biopsies comprised both epithelium and 
stromal tissue.  
Within 1 hour after obtaining tissues the explants were extensively washed. Then 
explants were either immediately treated with the Dendron 12 and infected with R5 
tropic strains or were pre-stimulated for 2 days in presence of IL-2 (R&D systems, 
Minneapolis, MN, USA) and PHA (Sigma-Aldrich, Saint Louis, Mo, USA) prior to X4 
tropic DPMVF exposure.  
Explants were pre-treated 30 minutes at 37°C  with different concentrations of 
Dendron 12. Afterwards explants were exposed to HIV-1 BaL, DU174 (both 2.6 x104 
TCID5050), 8g or DPMVF (both 104 TCID5050) in the continued presence of the  
6 
 
compound 3h at 37°C. Subsequently explants were washed with RPMI. Unstimulated 
explants were cultured in RPMI medium supplemented with 20% FBS, PS,LG 
(Euroclone) and gentamycin (Sigma-Aldrich) at 37°C and 5% CO2. Stimulated 
explants were cultured under the same conditions in presence of IL-2. Supernatants 
were collected 3 and 7 days post infection.  
 
p24 ELISA 
 p24 concentration in the supernatants was assayed by Alliance HIV-1 p24 Antigen 
kit (Perkin Elmer, Whaltam, MA, USA). Plates were read using the IMark microplate 
reader equipped with Microplate Manager ® 6 software (Biorad, Segrate, Italy). 
 
Toxicity on PBMCs 
PBMCs, purified from peripheral blood of healthy donors as described [23], were 
incubated with different concentrations of Dendron 12 for 3 or 7 days. The apoptosis 
was monitored evaluating the percentage of dead cells by staining with 7-AAD, 
(Beckman Coulter, Fullerton, CA, USA). Flow cytometric analyses were performed 
using a CYTOMICS FC-500 flow cytometer interfaced with CXP21 software 
(Beckman Coulter). 
 
MTT assay 
Toxicity of Dendron 12 was determined by a MTT based assay (Sigma-Aldrich). 
Viable explants reduce MTT to formazan crystals. Explants were cultured with 
increasing concentration of Dendron 12 diluted in medium culture  for 3 and 7 days. 
The 50% of medium culture (containing the different concentration of Dendron 12) 
was changed at day 3. After culturing, explants were washed and incubated in 
medium RPMI without phenol red plus 10% FBS and MTT. Formazan was dissolved 
by MTT solubilisation solution and formazan absorbance was measured at 595 nm. 
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Differentiation and treatment of MDDCs 
CD14+ monocytes were separated from PBMCs using the CD14+ microbeads 
(Miltenyi Biotech, Bergisch Gladbach, Germany) following manufacturer’s instruction. 
Monocytes were differentiated into iDCs by culturing them in presence of IL-4 (20 
ng/ml) and GM-CSF (20 ng/ml) (R&D Systems) for 6 days. DC-SIGN expression was 
checked by staining with anti human DC-SIGN-PE monoclonal antibody (clone 
AZND1, Beckman Coulter) and flow cytometric analysis. MDDCs were treated with 
Dendron 12. Supernatants were harvested and RNA extracted from cells after 3, 24 
and 72h. β chemokines concentration in culture supernatants was evaluated using 
DuoSet kits (R&D Systems).  
 
RNA Extraction and Real time PCR 
 RNA was extracted using the acid guanidium thiocyanate–phenol–chloroform 
method and purified from genomic DNA with RNase-free DNase (RQ1 DNase, 
Promega, Madison, WI,USA). RNA was reverse transcribed using random examer 
primers and M-MLV reverse transcriptase (Clontech, Palo Alto, CA, USA). cDNA 
quantification for MIP1α, MIP1β, RANTES and GAPDH was performed by real-time 
PCR (DNA Engine Opticon 2; MJ Research, Ramsey, MN, USA). Reactions were 
performed using a SYBR Green PCR mix (Finnzymes, Espoo, Finland). Results were 
expressed as ∆∆Ct and presented as ratios between the target gene and the 
GAPDH housekeeping mRNA. 
 
Surface plasmon resonance analysis 
Extracellular domain (ECD) of Langerin (residue 68-328) and DC-SIGN (residue 66-
404) were overexpressed and purified as described [28,29]. SPR experiments were 
performed on a Biacore 3000 using functionalized CM4 sensor chips and the 
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corresponding reagents from Biacore. Two flow cells were activated as described 
[30]. Flow cell one was blocked with ethanolamine and used as a control surface. 
The second one was treated with BSA-Manα1-3[Manα1-6]Man (Man-BSA, Dextra) 
(60 µg/mL) in 10 mM acetate buffer, pH 4. Remaining activated groups were blocked 
with ethanolamine. The final density immobilized on the surface of the second flow 
cell was 5200 RU. The Man-BSA used to functionalize CM4 chip harbours 12 
glycosylation sites. The affinities for DC-SIGN ECD and Langerin ECD of pseudo-
mannotrioside and D-mannose were estimated by an inhibition assay, as described 
[22,31]. Each lectin was injected onto the Man-BSA surface, at 20 µM alone or in 
presence of an increasing concentration of compounds. Injections were performed at 
5 µL/min using 25 mM Tris-HCl, pH 8, 150 mM NaCl, 4 mM CaCl2, and 0.005% of 
P20 surfactant as running buffer. The surface was regenerated by 1’ injection of 
50 mM EDTA, pH 8. The IC50 values were determined as described [22,31].  
 
Results 
Dendron 12 inhibits trans infection in presence of HIV-1 elevated viral load 
We firstly examined whether the Dendron 12 was able to inhibit the trans infection in 
the presence of elevated viral load. B-THP1/DC-SIGN cells were used as model to 
mimic HIV transmission to CD4+ T cells, as previously described [6,23,32]. B-
THP1/DC-SIGN cells were pre-incubated 30 minutes in the presence or in absence 
of Dendron 12 and then exposed to different inoculums of HIV-1 Bal. Then, B-
THP1/DC-SIGN cells were washed and co-cultured with activated CD4+ T cells. At 
lower viral concentration inhibition of BaL transmission to CD4+ T cells was almost 
complete. Even at higher viral load (40 and 80 TCID50) the Dendron 12 was able to 
counteract the transmission of the virus to CD4+ T lymphocytes (more than 92% of 
inhibition) (Fig.1a). 
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Selectivity towards DC-SIGN 
Both Langerin and DC-SIGN recognize Man9 on gp120, but have distinct specificities 
towards complex oligosaccharides [33-36]. Specificity of pseudo-mannotrioside 
ligand for Langerin and DC-SIGN was tested by competition experiments using 
surface plasmon resonance (SPR), as previously described [37]. A CM4 sensorchip 
were functionalized with BSA-Mannotriose and a fixed amount of the extracellular 
domain of DC-SIGN and Langerin, were injected over the surface in the presence or 
absence of pseudo-mannotrioside or mannose (control). From the inhibition curves 
(Fig. 1b), an IC50 of the two ligands towards each lectins was evaluated (Fig. 1c). A 
limited difference in favour of DC-SIGN was observed for mannose. On the contrary, 
pseudo-mannotrioside is 20 times more potent toward DC-SIGN than against 
Langerin. Moreover, pseudo-mannotrioside is 14 times more potent than D-mannose 
towards DC-SIGN. Indeed, the use of pseudo-mannotrioside allows real 
improvement in affinity and in selectivity.  
 
Inhibition of HIV-1 infection of human cervical tissue by Dendron 12 
Endocervical tissue was obtained from premenopausal women, HIV, HBV and HCV 
seronegative, undergoing planned therapeutic hysterectomy. Explants were exposed 
to HIV-1 in a non-polarised manner, analogous to condition of compromised 
epithelium in vivo. As the laboratory adapted R5 strain HIV-1 BaL is able to infect 
resting tissue [25], explants were not activated to mimic physiological conditions. 
Explants were pre-treated 30 minutes in absence or in presence of increasing 
concentration of Dendron 12 and then were exposed to BaL in the continued 
presence of compound. After washing to remove unbound Dendron 12 and virus, 
explants were maintained in culture up to 7 days. Data represent p24 levels and are 
presented as the mean of 5 independent experiments, using explants from separate 
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donors. Dendron 12 inhibited cervical explants BaL infection in dose dependent 
manner (Fig. 2). At the higher concentration tested, Dendron 12 reduced the infection 
by about 80%, at 3 and 7 days post infection.  
The ability of Dendron 12 to avert explant infection mediated by primary HIV-1 
isolates was also verified. R5 tropic isolate 8g was able to infect unstimulated tissue, 
but X4 tropic isolate DPMVF needed pre-activation to induce infection (not shown). 
Explants unstimulated or pre-activated 2 days with IL-2 and PHA were pre-treated 
with increasing concentration of Dendron 12 and infected respectively with 8g or 
DPMVF, as described before. Infection inhibition was dose dependent. At the 
concentration of 1mM, infection by both isolates was reduced by more than 85%. At 
0.05 mM Dendron 12 decreases by 56% (day 3) and by 40% (day 7) the infection 
mediated by 8g (Fig. 3a and b), but the inhibitory effect against DPMVF was largely 
lost (Fig. 3c and d). 
Furthermore we evaluated the capability of Dendron 12 to block explant infection by 
Clade C R5 tropic strain DU174. Unstimulated explants were pre-treated with the 
compound, exposed to DU174 and cultured as described. Dendron 12 reduced 
DU174 infection in dose dependent manner and by about 90% at 1 mM (Fig. 3e and 
f). 
 
Induction of β1 chemokines production by Dendron 12 
We wonder if, in addition to competitive inhibition of DC-SIGN, other mechanisms 
account for the antiviral effect of the compound 12. So we investigate if Dendron 12 
stimulates the production of factors interfering with HIV infection. Due to difficulty of 
isolating sufficient amounts of primary mucosal DCs, immature monocytes-derived 
dendritic cells (iMDDCs), that share with mucosal DCs similar features and DC-SIGN 
expression, were used as a model [38]. iMDDCs were treated with Dendron 12 for 3, 
24 and 72 hours. Expression and production of β chemokines MIP-1α, MIP-1β, and 
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RANTES following stimulation were analyzed by quantitative real time PCR and 
ELISA. The treatment increased expression level of mRNA specific for MIP-1α, MIP-
1β and RANTES (Fig. 4a-c) after 3 hours. Also MIP-1α, MIP-1β and RANTES 
production increased after 24 and 72 hours of stimulation (Fig. 4d-f).  
 
Evaluation of Dendron 12 toxicity  
Cytotoxicity against PBMCs was evaluated by labelling with 7-Amino-Actinomycin D 
(7-AAD), that identify non-viable cells, after Dendron 12 treatment. Compound 
exposure for 3 and 7 days did not alter significantly the viability of PBMCs (Fig. 5a 
and b). 
To assess toxicity of Dendron 12 towards cervical tissue, effect of non-polarized 
exposure of the compound on explants viability was monitored (Fig. 5c). After 3 and 
7 days treatment in absence or in presence of different concentration of Dendron 12, 
viability was evaluated by a MTT based assay. Viability of the compound treated 
explants was compared to viability of untreated control. No significant difference 
between control and treated explants was observed up to a concentration of 1mM 
(the higher concentration tested in assessment of compound efficacy against HIV-1 
infection).  
 
Discussion 
Three decades after HIV discovery HIV-AIDS pandemic continues and millions of 
people are infected every year. Thus, the development of effective, non-toxic and low 
cost topical microbicides represents a valid alternative approach to prevent the 
sexual transmission of HIV [3]. However, so far almost all compounds failed to 
prevent HIV transmission in efficacy trials. A recent exception was a vaginal gel 
formulation of tenofovir, that reduced HIV infection by 50% [39].  
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Tenofovir and other topical microbicides can prevent localized infection of target cells 
in genital mucosae. However DCs DC-SIGN+ internalize and transport HIV to 
secondary lymphoid organs, rendering the virus inaccessible to inhibitory effect of the 
microbicides. Therefore inhibition of DC-SIGN is essential to block HIV-1 uptake and 
dissemination from migratory DCs. 
We have previously reported that the tetravalent Dendron 12, was able to block 
almost completely the HIV-1 trans infection of CD4+ T cells at micromolar range [23]. 
This compound exerts its activity by competitive inhibition of HIV-1 gp120 binding to 
DC-SIGN. In our initial experiments we demonstrated that Dendron 12 (at the same 
concentration previously assayed) even in presence of higher viral loads  retains its 
ability to inhibit HIV-1 trans infection. This potent inhibitory activity is due both to 
elevate affinity for DC-SIGN of Dendron 12 pseudo-trisaccharide units and to high 
avidity of binding, guaranteed by the tetravalent presentation on the compound 
scaffold.  
Different DC-SIGN inhibitors have been described so far. Dendrons displaying 
complex oligomannoses in high density inhibited binding of gp120 to DC-SIGN with 
IC50 in nanomolar range [40]. Nevertheless the complexity of the oligosaccharides 
used limits the possibility of a therapeutic application. Gold nanoparticles displaying 
mannosyl oligosaccharides are potent inhibitors of DC-SIGN mediated HIV-1 trans 
infection of human PBMCs [41], but may have toxic effects because of gold 
accumulation. 
Unlike DC-SIGN, the C-Type lectin  Langerin, expressed on Langerhans cells (LCs) 
appears to play a protective role against HIV infection. LCs are located in the 
stratified mucosal epithelia of female and male genital tissue. Both DC-SIGN and 
Langerin recognise high mannose glycans on gp120 through their CRD. Recent data 
demonstrate that Langerin prevents HIV transmission by LCs, at least in the 
presence of low concentration of the virus, promoting rapid degradation and 
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clearance of HIV-1 [32-33]. Using a biosensor with a SPR detection method we 
showed that the Dendron 12 is much more selective for DC-SIGN than for Langerin. 
Considering the similarity between the CRD of DC-SIGN and Langerin, the fact that 
the Dendron 12 does not interfere with Langerin function is a remarkable advantage 
in view of developing new microbicides.  
The efficacy and the safety of the Dendron  12 were evaluated in a human cervical 
explants model. Endocervix is more susceptible to HIV-1, being lined by a single 
layer of columnar epithelium, and contain DCs DC-SIGN in the subepithelial region 
[4,5,24]. Explants were exposed to HIV-1 to mimic a condition of compromised 
epithelium in vivo; condition that highly increases the risk of HIV infection. 
R5-tropic viruses strains predominate during HIV-1 transmission in vivo and cause 
the majority of new infections [42]. The results obtained showed that Dendron 12 
strongly reduced the infection of cervical explants by different HIV-1 R5 tropic strains, 
such as BaL, the primary isolate 8g and the Clade C DU174. This may have a great 
impact, considering that Clade C is the most abundant subtype in all countries of 
Southern Africa and in some countries of eastern Africa and  Asia, areas where the 
majority of HIV-1 infected people resides [43,44]. 
Rare cases of HIV-1 infection by X4-tropic strains were observed in CCR5∆32 
homozygotes  and X4 tropic strain can infect immune activate human cervical tissue 
[25,42]. Dendron 12 was able  to inhibit DPMVF primary X4 tropic strain infection at 
higher concentration assayed, but this effect was in part lost at lower concentrations 
of the compound. 
Data obtained suggest that  Dendron 12 might have additional mechanisms of action 
besides competitive inhibition of HIV-1 binding to DC-SIGN. Flow cytometric studies 
indicate that treatment with Dendron 12 reduces DC-SIGN expression on B-
THP1/DC-SIGN [23]. This effect may be due to increased internalisation of the 
receptor after binding of the compound to DC-SIGN. 
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Furthermore Dendron 12 induced an augmentation of the production of β 
chemokines, such as MIP-1α, MIP-1β and RANTES, by iMDDCs. These β 
chemokines, natural ligands of CCR5,  suppress HIV-1 R5 tropic strain replication, 
competing with the binding of the virus to CCR5 or inducing receptor internalisation 
[45-47]. The Dendron 12, enhancing β chemokines production, could interfere, at 
least partially, with the direct infection of CCR5+ CD4+T lymphocytes and 
macrophages located in genital mucosae.  
The Dendron 12 do not reduce the vitality of PBMCs and of explants. However 
additional experiments, such as Rabbit Vaginal Irritation Assay [48], would be 
needed for a more accurate evaluation of potential toxic effects. 
Vaginal epithelium has limited permeability to particles greater than 30 nm [2]. 
However the diameter of Dendron 12 is certainly below that threshold, so the 
compound could enter and diffuse into intact mucosal tissue. Furthermore the 
Dendron 12 scaffold can be easily modified to improve absorption of the compound, 
without decreasing affinity to DC-SIGN.  
The tetravalent Dendron 12 prevents HIV trans infection of CD4+ T lymphocytes at 
micromolar range, even in presence of elevated viral load, displays high solubility in 
physiological media, a neglectable toxicity and a long lasting effect. Moreover it 
inhibits in dose dependent manner HIV-1 infection of human cervical explants. These 
features make the Dendron 12 a good candidate as a lead compound to develop new 
microbicide drugs. 
However the Dendron 12 inhibits 80-90% of cervical explants HIV-1 infection, but 
cannot block it completely. To overcome these limitations, structure of this compound 
can be improved in both the scaffold and the active pseudo-saccharide ligand to 
develop of new ligands of DC-SIGN more effective and easier to synthesize. 
Furthermore, Dendron 12 (or its derivatives) can be used in combination with other 
molecules directed against different HIV targets. In particular multivalent structures, 
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presenting on the same scaffold multiple copies of DC-SIGN and HIV co-receptors 
inhibitors, simultaneously blocking different HIV targets, could protect against 
different routes of HIV transmission.  
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FIGURE LEGENDS 
 
Fig. 1 Evaluation of Dendron 12 ability to inhibit HIV-1 Bal Trans infection in 
presence of increasing amounts of the virus (a) and selectivity to DC-SIGN 
(b,c). (a) After  pre-treatment with Dendron 12 (250 µm) or medium culture, B-THP-
1/DC-SIGN cells were pulsed with BaL 3 hours. After washing cells were co-cultured 
3 days with CD4+ T lymphocytes from healthy donors. Levels of infection were 
quantified by measuring p24 in the supernatants of co-cultures by ELISA. Data were 
obtained from 3 different healthy donors. Each donor was tested in duplicate. Values 
are mean ± SD. (b, c) SPR experiment results of DC-SIGN ECD and Langerin ECD 
binding to Man-BSA/dextran surface inhibition by pseudo-mannotrioside (psTri) and 
D-mannose. (b), inhibition curves, and (c) lectin selectivity histograms.  
 
Fig. 2.  Inhibition of endocervical  tissue infection mediated by HIV-1 Bal. After a 
30 minutes pre-treatment with the Dendron 12 or medium culture, endocervical 
explants were incubated 3 hours with BaL in the continued presence of indicated 
concentrations of  Dendron 12. Then explants were washed and cultured for 7 days. 
Infection was monitored by ELISA measurement of p24 in explant culture 
supernatants at day 3 (a) and 7 (b) post infection. Values represent the mean ±SD of 
5 independent experiments. ***p values < 0.001, **p values<0.01, *p values<0.05 
(Student T Test).  
 
Fig. 3. Inhibition of endocervical infection induced by HIV-1 primary isolates 
(8g and DPMVF) and  HIV-1clade C DU174. (a,b,e,f) Unstimulated explants were 
pre-treated  30’ with Dendron 12 or medium culture and challenged with 8g or 
23 
 
DU174. (c,d) Explants immuno-stimulated  were pre-treated 30’ with Dendron 12 or 
medium culture and infected with DPMVF.  
After washing explants were put in culture. Infection was monitored by ELISA 
measurement of p24 in explant culture supernatants at day 3 and 7 post infection. 
Values represent the mean ±SD of 3 independent experiments. *p values<0.05 
(Student T Test) 
 
Fig. 4. β chemokines induction upon Dendron 12 (250µM) stimulation of human 
iMDDCs from healthy donors. (a-c) β chemokines expression following 3 h Dendron 
12 (250 µM) treatment. mRNA levels of MIP1α (a), MIP1β (b) and RANTES (c) were 
assessed by quantitative real time PCR. Expression is normalized to GAPDH and 
shown as fold changes expression from the unstimulated sample, set as 1. (d-f) β 
chemokines protein production after stimulation with Dendron 12 (250 µM). The 
concentration of MIP1α (d), MIP1β (e) and RANTES (f) in the culture supernatants 
was assayed by ELISA at 24 and 72h. (a-f). Values represent the mean ±SD. 
 
Fig. 5. Toxicity of compound 12. (a and b) Percentage of 7-AAD positive (non 
viable) PBMCs after 3 or 7 days of incubation with different concentrations of 
Dendron 12 (0.25 mM, 0.5 mM and 0.1 mM), or in the absence of the inhibitor 
(Medium). Percentage of 7-AAD was determined by flow cytometry. Experiments 
were performed on PBMCs from 3 healthy donors. Values are mean ± SD.  
Effect of Dendron 12 on cervical explants viability (c). Endocervical explants, derived 
from the same donors, were exposed in non polarised manner to Dendron 12 or 
culture medium (control) for 3 and 7 days.  Effect of Dendron 12 on tissue viability 
was determined by the MTT assay. Explants  were weighted  to normalize optical 
density of formazan yielded. Viability was expressed as percentage. Experiments 
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were performed on explants from 3 donors. Data are reported as the average percent 
viability (± SD). 
 
 
 
 
 
